medication adherence News
-
Berkshire Biomedical, Developers of COPA, Featured as a 2022 Top Texas Tech Startup in StartupCity Magazine
Berkshire Biomedical Corporation (“Berkshire” or “the Company”) is focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness. The Company announced today that its lead product, the Computerized Oral Prescription Administration System (COPA™), has been honored as a 2022 Top Texas Tech Startup in the ...
-
RemetricHealth’s Integrated Telehealth/Remote Patient Monitoring Solutions Bridge the Gap Between Patients and Providers Amid Ongoing COVID-19 Crisis
RemetricHealth, a leading remote patient monitoring (RPM) and telehealth services company that has been serving the healthcare industry for more than a decade, has announced that its telehealth capabilities, in conjunction with its biometric monitoring devices, are helping connect patients and providers in a time when continuity of care can be challenging due to COVID-19. The telehealth model is ...
-
Berkshire Biomedical Appoints John E. Timberlake as CEO
Berkshire Biomedical, LLC (“Berkshire” or “the Company”), a privately-held digital health company developing a revolutionary virtual care prescription drug delivery and management system only for the Intended User, today announced the appointment of John E. Timberlake as President and Chief Executive Officer. In addition, Mr. Timberlake will serve as a member of the ...
-
Novel Drug Delivery System Unveiled: CD Formulation Launches Oral Thin Films Technology
In a groundbreaking development in the field of pharmaceuticals, CD Formulation, a prominent drug formulation company, has announced the launch of Oral Thin Film Technology. This cutting-edge drug delivery system is poised to revolutionize medication administration, offering patients a more convenient and effective treatment method. Oral Thin Film Technology is a user-friendly drug delivery ...
-
Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ ...
-
Flosonics Medical receives over $1.5 million through the province’s Ontario Together Fund
The investment will allow Flosonics Medical to scale up the manufacturing and distribution of cutting-edge medical solutions while strengthening the province’s pandemic supply chain Flosonics Medical received over $1.5 million through the province’s Ontario Together Fund to scale up the manufacturing and distribution of FloPatch, the world’s first wearable wireless Doppler ...
-
Evolution of ePROM: Advancements, Concerns, and the Way Forward
Patients’ directly reported outcomes in certain rare and chronic diseases are considered reliable for understanding the disease’s natural history, palliative treatments that focus primarily on symptom control, and quality of life. Electronic Patient-Reported Outcome Measures (ePROMs) are now allowing these patients to self-report health conditions and treatment effectiveness ...
-
McKesson foundation awards $1.5 million to researchers studying how mobile technology can help patients manage diabetes
The McKesson Foundation today announced the six recipients of $1.5 million in research grants as part of its Mobilizing for Healthsm initiative to improve the health of underserved populations with chronic diseases through the use of mobile-phone technology. The Mobilizing for Healthsm grants, of up to $250,000 each, will support studies on diabetes care and management at six esteemed U.S. ...
By 3BL Media
-
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced completion of the formulation study for its third asset, CTx-2103, for the management of anxiety-related disorders. The study was ...
By Cingulate
-
Accenture HealthTech Innovation Challenge Names Eight Finalists
Accenture (NYSE: ACN) has named eight companies as finalists in the Accenture HealthTech Innovation Challenge, which brings together leading-edge startups with prominent health companies to tackle some of North America’s greatest health challenges. Attracting more than 2,600 startup applicants in the past five years, the Accenture HealthTech Innovation Challenge supports finding innovative ...
-
Berkshire Biomedical to Present at the LSI USA ’22 Emerging Medtech Summit
Berkshire Biomedical Corporation (“Berkshire” or the “Company”), focused on developing its proprietary drug dispensing technology to enhance patient wellness, announced today that John Timberlake, Chief Executive Officer, will present at the third annual Life Science Intelligence (LSI) USA '22 Emerging Medtech Summit on March 17, 2022 at 2:55 pm PT. The presentation will ...
-
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs. This is the second year of this unique program aimed at eliminating barriers to care for ...
-
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia Sustained Drug Delivery Technolog
Melbourne, Australia – February 17, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the Phase IIa study of its PA5108 Ocular Implant for the treatment of Primary Open-Angle ...
-
Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). ...
-
The Ultimate List of Attractive MedTech M&A Targets
Updated May 12, 2021 to reflect 10 new additions, based on recent analyst reports. We’ve also updated the existing companies on the list to reflect recent business developments. From time to time, medtech analysts will call out companies in the private sector that they believe investors should be keeping tabs on. Here is our ultimate list, compiled from analyst reports, of private ...
-
FPI Explores the Future of Cognitive Healthcare at the 87th China International Medical Equipment Fair (CMEF)
The 87th China International Medical Equipment Fair (CMEF) opened on 14 May at the National Convention and Exhibition Centre (Shanghai). The exhibition is a trendsetter in the global medical device industry and a "top tier" medical event, with brand representatives from more than 20 countries and regions from around the world showcasing sophisticated products spanning the entire industry chain ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you